142 related articles for article (PubMed ID: 38796779)
41. A Case of Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab: A Case Report.
Shibuya R; Baba K; Furuta R; Maesaka H; Hirosawa H; Bando T; Oshima A; Onoda H; Nukui T; Dougu N; Joho S; Nakatsuji Y
Intern Med; 2024 Jan; ():. PubMed ID: 38171860
[TBL] [Abstract][Full Text] [Related]
42. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
43. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
Gosser C; Al Bawaliz A; Bahaj W; Chesney J; Ranjan S
Cureus; 2023 Nov; 15(11):e49007. PubMed ID: 38111441
[TBL] [Abstract][Full Text] [Related]
44. Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.
Virgen CA; Sparks JA; Nohria A; O'Hare MJ; Goyal A; Said JT; Tawa M; LeBoeuf NR; Kupper TS; Fisher DC; Larocca C
Oncologist; 2023 Aug; 28(8):e694-e698. PubMed ID: 37285523
[TBL] [Abstract][Full Text] [Related]
45. Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors.
Schwab A; Assaad M; Hamadi R; Zurndorfer J; Abi Melhem R; Holtzbach J; Loeffler J; Ibrahim M
J Med Cases; 2022 Nov; 13(11):530-535. PubMed ID: 36506763
[TBL] [Abstract][Full Text] [Related]
46. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series.
Marco C; Simó M; Alemany M; Casasnovas C; Domínguez R; Vilariño N; Calvo M; Martín-Liberal J; Brenes J; Sabater-Riera J; Bruna J; Velasco R
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614930
[TBL] [Abstract][Full Text] [Related]
47. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
Soman B; Dias MC; Rizvi SAJ; Kardos A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
[TBL] [Abstract][Full Text] [Related]
48. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
Seki M; Suzuki S
Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
[TBL] [Abstract][Full Text] [Related]
49. Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life-threatening continuum of neuromuscular and cardiac toxicity.
Rota E; Varese P; Agosti S; Celli L; Ghiglione E; Pappalardo I; Zaccone G; Paglia A; Morelli N
eNeurologicalSci; 2019 Mar; 14():4-5. PubMed ID: 30533536
[No Abstract] [Full Text] [Related]
50. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
[TBL] [Abstract][Full Text] [Related]
52. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series.
Wong EYT; Yong MH; Yong KP; Tan EH; Toh CK; Kanesvaran R; Takano A; Ng QS
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e262-e267. PubMed ID: 32985078
[TBL] [Abstract][Full Text] [Related]
53. [Clinical Features of Myasthenia Gravis as an Immune-related Adverse Event].
Suzuki S
Brain Nerve; 2024 Jan; 76(1):27-32. PubMed ID: 38191136
[TBL] [Abstract][Full Text] [Related]
54. Giant cell myositis and myocarditis revisited.
Oflazer P
Acta Myol; 2020 Dec; 39(4):302-306. PubMed ID: 33458585
[TBL] [Abstract][Full Text] [Related]
55. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.
Fazel M; Jedlowski PM
Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226
[TBL] [Abstract][Full Text] [Related]
56. Multiple Immune-Related Adverse Event Overlap in Two Patients Treated with Pembrolizumab.
Jenkins JD; Camara-Lemarroy C; Joseph JT; Brust T
Can J Neurol Sci; 2022 Jan; 49(1):133-135. PubMed ID: 33726876
[No Abstract] [Full Text] [Related]
57. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
58. Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.
Wang S; Peng D; Zhu H; Min W; Xue M; Wu R; Shao Y; Pan L; Zhu M
Front Oncol; 2022; 12():1053370. PubMed ID: 36568231
[TBL] [Abstract][Full Text] [Related]
59. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
60. Paraneoplastic myopathies.
Mammen AL
Handb Clin Neurol; 2024; 200():327-332. PubMed ID: 38494286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
